問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Neurology

更新時間:2023-09-19

王署君Wang, Shuu-Jiun
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

篩選

List

31Cases

2016-02-01 - 2020-04-02

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate LY2951742 in patients with chronic migraine — the REGAIN trial.
  • Condition/Disease

    Chronic migraine

  • Test Drug

    LY2951742

Participate Sites
5Sites

Terminated5Sites

2013-05-20 - 2018-12-31

Phase III

A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease.
  • Condition/Disease

    mild to moderate Alzheimer’s disease

  • Test Drug

    masitinib

Participate Sites
6Sites

Terminated6Sites

2021-05-01 - 2023-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2008-03-06 - 2009-02-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-08-01 - 2023-05-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2017-07-01 - 2020-06-09

Phase III

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia
  • Condition/Disease

    Trigeminal Neuralgia

  • Test Drug

    BIIB074

Participate Sites
5Sites

Not yet recruiting5Sites

2016-09-30 - 2018-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer′s Disease Dementia (The DAYBREAK Study)
  • Condition/Disease

    Mild Alzheimer′s Disease

  • Test Drug

    LY3314814

Participate Sites
10Sites

Terminated10Sites

2008-01-01 - 2012-07-31

Phase III

Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo
  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    LY450139

Participate Sites
5Sites

Terminated5Sites

2015-10-01 - 2020-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3 4